Mutations in fibroblast growth factor (FGF) receptors are responsible for a variety of skeletal birth defects, but the underlying mechanisms responsible remain unclear. Using a mouse model of thanatophoric dysplasia type II in which FGFR3 K650E expression was directed to the appendicular skeleton, we show that the mutant receptor caused a block in chondrocyte differentiation specifically at the prehypertrophic stage. The differentiation block led to a severe reduction in hypertrophic chondrocytes that normally produce vascular endothelial growth factor, which in turn was associated with poor vascularization of primary ossification centers and disrupted endochondral ossification. We show that the differentiation block and defects in joint formation are associated with persistent expression of the chondrogenic factor Sox9 and down-regulation of b-catenin levels and activity in growth plate chondrocytes. Consistent with these in vivo results, FGFR3 K650E expression was found to increase Sox9 and decrease b-catenin levels and transcriptional activity in cultured mesenchymal cells. Coexpression of Fgfr3 K650E and Sox9 in cells resulted in very high levels of Sox9 and cooperative suppression of b-catenin-dependent transcription. Fgfr3 K650E had opposing effects on Sox9 and b-catenin protein stability with it promoting Sox9 stabilization and b-catenin degradation. Since both Sox9 overexpression and b-catenin deletion independently blocks hypertrophic differentiation of chondrocytes and cause chondrodysplasias similar to those caused by mutations in FGFR3, our results suggest that dysregulation of Sox9 and b-catenin levels and activity in growth plate chondrocytes is an important underlying mechanism in skeletal diseases caused by mutations in FGFR3.
INTRODUCTION
Fibroblast growth factor receptor 3 (FGFR3) is one of four FGFR family members activated by binding to fibroblast growth factor (FGF) ligands. Ligand binding stimulates receptor tyrosine kinase activity, which initiates intracellular signaling cascades that influence a variety of cell behaviors. A number of different mutations in FGFR3 have been identified that inappropriately activate its tyrosine kinase activity, and when present in the germline, these mutations can cause a variety of related skeletal birth defect syndromes. These include G380R mutation in the transmembrane domain of FGFR3 which causes classical achondroplasia, R248C in the receptor linker region that causes a more severe syndrome called thanatophoric dysplasia type I (TDI) and K650E and K650M mutations in the kinase domain that cause TDII and Severe Achondroplasia Developmental Delay and Acanthosis Nigricans (SADDAN), respectively. The TDII mutation (K650E) has the most severe consequences, resulting in embryonic or neonatal lethality (1, 2) . There is considerable similarity and overlap between the types of bone dysplasias caused by the various FGFR3 mutations, with their severity generally linked to the degree of aberrant hyperactivation of the mutant receptors (3) . These findings suggest a common underlying mechanism that is influenced in a quantitative fashion depending on the mutation.
A defining feature of bone dysplasias caused by FGFR3 mutations is a distinct shortening of the long bones. FGFR3 is expressed in the proliferative zone of the cartilaginous growth plate of growing bones and considerable evidence indicates that the reduced longitudinal growth in bone dysplasia syndromes caused by mutant hyperactive FGFR3 is at least † These authors contributed equally to this work. * To whom correspondence should be addressed. Tel: +1 5032213438; Fax: +1 5032213451; Email: pjh@shcc.org # The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com Human Molecular Genetics, 2012, Vol. 21, No. 21 4628-4644 doi:10.1093/hmg/dds305 Advance Access published on July 26, 2012 partly a consequence of suppressed chondrocyte proliferation (1) . Analysis of mouse models of SADDAN (4) and TDII (5) suggests that disrupted endochondral ossification and bone growth are also associated with the suppression of chondrocyte terminal differentiation. Despite these findings, the molecular mechanisms that act downstream of mutant FGFR3 in these disease syndromes and are responsible for defects in chondrocyte proliferation and differentiation remain unclear.
In mouse limbs, chondrogenesis is initiated at approximately embryonic day (E) 10 in the center of limb buds where undifferentiated mesenchymal cells condense. Expression of the high-mobility group transcription factor Sox9 is induced in the precartilaginous condensation and plays an essential role in the formation of cartilage (6, 7) . While Sox9 is required for the initial production of chondrocytes, it also plays an important role in the further development and growth of the cartilage template (7 -9) . Growth of the cartilage template occurs within the growth plate through the proliferative expansion and differentiation of chondrocytes. In the growth plate, Sox9 is expressed in progenitor or 'resting' chondrocytes, proliferating chondrocytes and chondrocytes in the initial stage of differentiation (prehypertrophy), but is then abruptly downregulated as these cells differentiate into non-proliferative and terminally differentiated hypertrophic chondrocytes (10, 11) . The production of hypertrophic chondrocytes supports endochondral ossification at least in part by producing an extracellular matrix and growth factors such as vascular endothelial growth factor A (Vegfa) conducive to the invasion of blood vessels and osteoblasts into cartilage (12) . Sox9 downregulation in hypertrophic chondrocytes is thought to play a critical function in endochondral growth and ossification since its forced expression in growth plate chondrocytes suppressed the production of hypertrophic cells and Vegfa expression, resulting in compromised vascularization at the ossification front and a severe chondrodysplasia (7, 8) . In apparent support of these findings, a recent study showed that Sox9 directly represses the Collagen type 10a1 (Col10a1) gene, whose expression is initiated in prehypertrophic chondrocytes concomitant with Sox9 down-regulation (13) . However, there is also evidence that Sox9 plays a role in promoting hypertrophic chondrocyte differentiation. Both Ikegami et al. (9) and Dy et al. (14) showed that the deletion of Sox9 in chondrocytes resulted in apoptosis and the loss of Col10a1-positive cells. Taken together, these studies indicate that maintaining proper Sox9 regulation is critical for growth plate function, with both premature termination and ectopic expression capable of disrupting chondrocyte differentiation and endochondral ossification.
In addition to Sox9 directly regulating a variety of genes that promote and define chondrocyte identity and behavior (15) , it can interact with b-catenin, a multipurpose protein which functions as a transcriptional cofactor for Tcf/Lef transcription factors to drive canonical Wnt signaling (16) . Interaction between Sox9 and b-catenin can lead to their mutual proteosomal destruction and overexpression of Sox9 in cells was shown to effectively deplete b-catenin (17, 18) . Sox9 can also suppress b-catenin transcriptional activity independent of b-catenin degradation, possibly by interfering with b-catenin -Tcf/Lef interactions (18) . This ability of Sox9 to down-regulate b-catenin levels and activity may be relevant during early skeletal development where Wnt/b-catenin signaling plays an important role in directing fate determination of mesenchymal progenitor cells toward the osteoblast lineage (19) (20) (21) . However, despite acting to suppress the chondrogenic lineage in undifferentiated limb bud mesenchyme (19, 20) , b-catenin is later expressed in proliferating and differentiating chondrocytes of the growth plate where it plays a role in promoting hypertrophic differentiation and endochondral ossification (17, 22) . Similar to the consequences of forced expression of Sox9 in chondrocytes, the conditional deletion of b-catenin or b-catenin inhibition in growth plate chondrocytes leads to decreased chondrocyte proliferation, delayed hypertrophic chondrocyte differentiation and suppression of Vefga expression (17, 23, 24) . Taken together with Sox9 deletion and overexpression results described above, these studies support the notion that Sox9 -b-catenin interactions act to regulate the expansion and proper differentiation of chondrocytes in the growth plate. Furthermore, the finding that FGF signaling can regulate Sox9 expression (25) raises the possibility that deregulated expression of Sox9 and its impact on b-catenin levels and activity in the growth plate might contribute to defects in endochondral ossification associated with skeletal dysplasia syndromes caused by mutations in FGFR3.
Using a mouse model of TDII, we show here that mutant Fgfr3 causes an initial expansion of Sox9-positive cartilage and that failed progression of growth plate chondrocytes to hypertrophy and poor endochondral ossification in TDII is associated with persistent Sox9 expression and a severe reduction in vascularization of the primary ossification center. Persistent Sox9 expression was associated with reduced b-catenin levels and canonical Wnt transcriptional activity in the growth plate and articular cartilage, where defects in endochondral ossification and joint formation arise, respectively, in TDII mice. Consistent with these in vivo data, Fgfr3 K650E expression in cultured cells was found to promote Sox9 accumulation by increasing Sox9 protein stability and effectively block b-catenin-dependent transcriptional activity. Our data suggest that disruption of b-catenin -Sox9 homeostasis by mutant hyperactivated FGFR3 constitutes an important underlying mechanism in TDII and potentially other skeletal disorders caused by mutations in FGFR3.
RESULTS

Conditional activation of FGFR3 K644E in limb bud mesenchyme
To study endochondral skeletal development in TDII, we used mice containing a K644E (equivalent to K650E in humans) knockin mutation whose expression is initiated upon the Credependent removal of a Stop/flox cassette (5). These mice were mated with Prx1-Cre mice (26) for preferential targeting to early limb bud mesenchyme. Analysis of the limb skeleton of Prx1-Cre;TDII mice by Alcian blue/Alizarin red staining at E15.5 and E18.5 ( Fig. 1A and B) revealed shortened skeletal elements characterized by very small primary ossification centers and a higher ratio of cartilage to mineralized bone in the long bones. The tibia of Prx1-Cre;TDII mice contained densely packed chondrocytes throughout the growth plate, Human Molecular Genetics, 2012, Vol. 21, No. 21 4629 from the epiphyseal head and articular regions to the area adjacent to the primary ossification center where distinctive hypertrophic cells are normally found (Fig. 1C) . In addition to these phenotypes, which were similar to those described in mice in which Fgfr3 K644E expression was initiated in the germline (5), Prx1-Cre;TDII mice consistently exhibited fusions between the articular surfaces of the humerus and ulna (elbow joint) and the tibia and femur (knee joint) (Fig. 1A-C) . Joints distal to the ulna/radius and tibia/fibula were not fused (Fig. 1B) . Unlike germline activation of Fgfr3 K644E , Prx1-Cre;TDII mice are viable, and bone staining at postnatal day 5 (P5) and P20 showed that the cartilaginous templates had fully ossified, but that the long bone elements remained very short and the knee and elbow joint fusions persisted (not shown).
Deregulated expression of Fgfr3 and Sox9 and disruption of chondrocyte differentiation during early skeletogenesis
Studies performed by Iwata et al. (5) showed that defects in chondrocyte differentiation and morphology were apparent in limb skeletal elements of TDII mice at E14.5 -E15.5.
These data suggested that the disease process is initiated in TDII prior to the commencement of endochondral ossification. To investigate this possibility, we examined the expression of Fgfr3 and markers of chondrocytes and osteoblasts by in situ hybridization at E11.5 and E12.5, limb bud stages when the cartilaginous condensations are expanding and elaborating into patterned cartilaginous elements. Fgfr3 was expressed at these stages in the same locations as Sox9, which defines the developing cartilage ( Fig. 2A-D) . Indeed, the broadened Sox9 expression in cartilage anlagen of the autopod at E12.5, but not at E11.5, suggests that Fgfr3 K644E promotes Sox9 expression and/or chondrogenesis after commitment to the chondrogenic lineage. The expression of Runx2, encoding the central regulator of the osteoblast lineage, and Gdf5, which encodes a ligand of the transforming growth factor-b superfamily involved in chondrogenesis and joint formation (27) , were similar in control and Prx1-Cre;TDII (Fig. 2E -H) .
At E14.5, the growth plate architecture was established in control tibias as indicated by the production of differentiated enlarged/hypertrophic chondrocytes that express Col10a1, and the mineralization of the bone collar had initiated based on von Kossa staining ( Fig. 2I and J). Prx1-Cre;TDII tibias from siblings were larger and similarly showed strong Col10a1 expression in their mid-section, but showed less mineralization and the Col10a1-positive cells remained more densely packed and failed to fully adopt the enlarged, hypertrophic morphology seen in control tibias ( Fig. 2I and J and also see Figs 1C and 3L and M). Invasion of Col1a1-positive osteoblasts from the perichondrium and associated endochondral ossification was similarly lacking in control and Prx1-Cre;TDII tibias at this stage (Fig. 2J) . In both control and Prx1-Cre;TDII tibias, Fgfr3 and Sox9 were coexpressed, with expression highest in the proliferative region of the growth plate ( Fig. 2K and L) . In control tibia, Fgfr3 and Sox9 expression overlapped with Col10a1 expression only in prehypertrophic cells as defined by their expression of Indian Hedgehog (Ihh) and Parathyroid hormone 1 receptor 1 (Pth1r) (Fig. 2M and N, see the region defined by dashed lines). In contrast, Fgfr3 and Sox9 expression extended further into the mid-section of Prx1-Cre;TDII tibias and overlapped with all or most cells expressing Col10a1 (Fig. 2K and L). Ihh and Pth1r expression was throughout the Col10a1-positive mid-section of Prx1-Cre;TDII tibias ( Fig. 2M and  N) . These data suggest that mutant Fgfr3 functions to specifically suppress prehypertrophic to hypertrophic differentiation.
Iwata et al. (5) previously noted increased proliferation in growth plates of femurs in TDII model mice at E15.5 based on [ 3 H]thymidine incorporation and proliferating cell nuclear antigen labeling. However, we found only little or no difference in proliferation in the tibia growth plate of Prx1-Cre;TDII at E14.5 based on BrdU incorporation (Supplementary Material, Fig. S1 ). Thus, the increased size of cartilage elements in the TDII embryo observed at E14.5 may be related to both a slight increase in proliferation and a differentiation block that leads to the excessive accumulation of prehypertrophic cells. In addition, these data suggest that the pronounced bowing of TDII proximal skeletal elements seen at E14.5 (and later stages; Fig. 1A and B) might be linked to defects in chondrocyte differentiation beginning prior to the onset of endochondral ossification. 
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Human Molecular Genetics, 2012, Vol. 21, No. 21 Consistent with reduced production of Vegfa, the extensive vasculature of the primary ossification center marked by expression of PECAM (CD31) found in control mice was severely diminished in Prx1-Cre;TDII mice at E16.5 and E18.5 ( Fig. 3J and K) . A paucity of erythrocyte-containing blood vessels near the chondro-osseous junction in Prx1-Cre;TDII mice at E16.5 was also apparent in histological sections (Fig. 3L ). Osteoblasts located in the perichondrium emigrate into the cartilage template laid down by hypertrophic chondrocytes along blood vessel tracks. Consistent with decreased vascularization and defective emigration of osteoblasts, expression of the osteoblast markers Col1a1 and Osteocalcin (Osc) were reduced in the primary ossification center of TDII tibia particularly at the chondro-osseous junction ( Fig. 3M and N) . Expression of MMP13, encoding a protease involved in the resorption of hypertrophic cartilage and the remodeling of newly deposited trabecular bone during long bone development (28,29) appeared to not be altered in Prx1-Cre;TDII tibias (Supplementary Material, Fig. S2 ). Tartrate-resistant acid phosphatase staining of osteoclasts appeared stronger in the primary ossification center of Prx1-Cre;TDII tibias (Supplementary Material, Fig. S2 ), but as noted previously (5), this may be an indirect consequence of poor ossification.
Taken together, these data suggest that a key mechanism underlying the poor endochondral ossification in TDII is a prehypertrophic stage differentiation block that prevents sufficient production of Vegfa-expressing hypertrophic cells and associated vascularization and osteoblast emigration into the cartilage template.
Down-regulation of b-catenin and canonical Wnt/ b-catenin activity in growth plate and joint chondrocytes The data described above indicated an association between persistent Sox9 expression and a prehypertrophic differentiation block in TDII. Previous studies showing that Sox9 protein levels are negatively regulated by b-catenin and that b-catenin deletion in the growth plate prevents chondrocyte hypertrophy and causes a chondrodysplasia phenotype with similarities to TDII (17, 18) raised the possibility that aberrant b-catenin activity might contribute to the differentiation block in the TDII growth plate. We therefore generated Prx1-Cre;TDII mice containing a b-galactosidase reporter (TOPGal) (30) for canonical Wnt/b-catenin activity and examined TOPGal activity in the developing limb skeleton. At E12.5, TOPGal activity in control embryos was strongest in the central and proximal forelimb and hindlimb buds (Fig. 4A) , consistent with the region where the radius/ulna and tibia/fibula cartilage templates are forming and Sox9 levels are low (Fig. 2D) . In contrast, staining in the developing bones of the autopod where Sox9 levels are high (Fig. 2D ) was minimal in control limb buds (Fig. 4A) . Consistent with Fgfr3 K644E -suppressing b-catenin activity, Prx1-Cre;TDII limb buds at E12.5 exhibited lower TOPGal staining than control limb buds ( Fig. 4A ). At E14.5, prior to the onset of endochondral ossification, there was widespread TOPGal staining in proximal tibia sections of control embryos and this was reduced in tibia sections of Prx1-Cre;TDII siblings ( Fig. 4B ). Whole-mount staining of E15.5 forelimbs showed a general reduction in TOPGal staining in the skeletal elements ( Fig. 4C ) and E15.5 sections showed reduced staining in both growth plate chondrocytes and in articular chondrocytes of the elbow joint in Prx1-Cre;TDII embryos ( Fig. 4D ). Whole mount staining of proximal tibias at E18.5 similarly showed reduced TOPGal staining in the growth plate region and at the tibia-femur joint (Fig. 4E) .
Further analyses of the E16.5 proximal tibia growth plate showed reduced TOPGal and b-catenin staining in cells of the proliferative zone, hypertrophic region immediately adjacent to ossification front where b-catenin is thought to contribute to Vegfa transcription (24) and at epiphyseal head regions where articular cartilage and joint formation normally occurs ( Fig. 4F and G and see more below). c-Myc, a b-catenin target gene (31) and a key regulator of chondrocyte proliferation in the growth plate (32) , was decreased in the growth plate of Prx1-Cre;TDII embryos at E16.5 ( Fig. 4H ). Consistent with low b-catenin and c-Myc, proliferation was markedly decreased at E16.5 in the TDII growth plate (Fig. 4I ). Since cell proliferation was not significantly affected at E14.5 (Supplementary Material, Fig. S1 ), these data suggest that chronic FGFR3 signaling is required for decreased chondrocyte proliferation. Perhaps more importantly, these data reveal a strong correlation between mutant Fgfr3 expression, decreased b-catenin expression and activity and a failure to down-regulate Sox9.
Defective joint formation in Prx1-Cre;TDII mice is associated with b-catenin down-regulation and inappropriate FGFR3 and Sox9 expression
To investigate defective knee joint formation in Prx1-Cre;TDII embryos, we examined markers of joint formation and articular cartilage together with additional histological characterization. The joint specification marker Gdf5 was expressed in cells of the knee joint region at E14.5 in both control and sibling Prx1-Cre;TDII embryos, but its expression was more dispersed and less defined in the TDII joint (Fig. 5A ). Apoptotic cells were present in the joint space of control embryos, but there was a clear lack of TUNEL staining in the presumptive knee-forming region of Prx1-Cre;TDII at E14.5 (Fig. 5B) . Histological examination showed morphological changes consistent with the initiation of knee joint formation in Prx1-Cre;TDII tibias, but separation between tibia and femur cartilage failed (Fig. 5C and D) . Articular chondrocytes have a distinctive morphology and arrange in a more dense architecture at the joint surface and these features were absent in the presumptive knee joint-forming region of Prx1-Cre;TDII mice ( Fig. 5C and D, red arrows) . These data are consistent with a previous study showing that transgenic expression of Fgfr3 G380R caused joint fusions (33) and suggest that mutant Fgfr3 acts to prevent chondrocytes in the presumptive knee-forming region to adopt the articular chondrocyte fate required for joint formation.
In addition to its functions in the growth plate, canonical Wnt/ b-catenin activity plays important roles in the development and maintenance of articular cartilage of synovial joints. In the absence of b-catenin, articular chondrocytes are prone to differentiate into chondrocytes with morphological characteristics and molecular markers more typical of the growth plate chondrocytes and can result in joint fusions (33 -35) . Consistent with results described above showing down-regulation of b-catenin protein levels and canonical Wnt/b-catenin activity in the growth plate, TOPGal staining and b-catenin protein levels were down-regulated in presumptive joint-forming regions, particularly at the epiphyseal surfaces of humerus and ulna where articular chondrocytes reside ( Fig. 5E and F) . Along with reduced b-catenin, articular cartilage markers Lubricin (Proteoglycan 4) and Vinculin were low or absent in the knee joint-forming region of Prx1-Cre;TDII embryos ( Fig. 5G and H) . FGFR3 was found sporadically in cells adjacent to the forming joint of control embryos, but not in articular chondrocytes at the joint boundary (Fig. 5I) . In contrast, Prx1-Cre;TDII embryos showed robust expression in most if not all cells of the presumptive knee joint-forming region (Fig. 5I) . Sox9 RNA and protein, as well as the Sox9 target gene Collagen 2a1 (Col2a1), showed an expression pattern similar to Fgfr3 (Fig. 5J -L) . Finally, Wnt/b-catenin activity plays an important role in promoting the proliferation of articular chondrocytes (35) , but the distinctive pattern of cell proliferation at the knee joint-forming region in controls was lost in Prx1-Cre;TDII embryos (Fig. 5M) . Together, these results show a close association between Sox9 expression and b-catenin deficiency with failed joint formation in TDII.
Fgfr3
K650E increases the pool of phosphorylated b-catenin targeted for degradation and decreases total b-catenin
The observation that b-catenin levels and canonical Wnt signaling is down-regulated in the TDII growth plate and joints prompted us to investigate the effect of ectopic Fgfr3 K650E on b-catenin levels and activity and Sox9 expression in the mouse multipotent mesenchymal cell line C3H10T1/2. Whereas Fgfr3 K650E had little or no effect on b-catenin mRNA levels (data not shown), it caused a decrease in endogenous b-catenin protein (Fig. 6A) . Phosphorylation of b-catenin at S33,S37,T41 promotes its proteosomal degradation, and despite lower total b-catenin levels in Fgfr3 K650E -expressing cells, phosphorylated b-catenin (p-b-catenin) were comparable in control and Fgfr3 K560E cells (Fig. 6A ). Sox9 levels are low in C3H10T1/2 cells and in contrast to b-catenin were slightly increased in Fgfr3 K650E -expressing cells. Expression of Tcf4 and Tcf1 were decreased in Fgfr3 K650E -expressing cells, but Lef1 levels were increased (Fig. 6A) and present in the nucleus (Supplementary Material, Fig. S3 ).
In addition to reducing b-catenin protein, Fgfr3 K650E altered its subcellular distribution (Fig. 6B) . Unlike control cells, which showed mostly diffuse cytoplasmic and plasma membrane localization, b-catenin was frequently and aberrantly associated with intracellular vesicles in Fgfr3 K650E -expressing cells (Fig. 6B) . Sox9 was detected in the nucleus of most, but not all, cells in both untransfected and Fgfr3 K650E -expressing cells, but staining was generally more intense in Fgfr3 K650E -expressing cells (Fig. 6B) . Additionally, C3H10T1/2 cells stably expressing Fgfr3 K650E exhibited severely altered cell morphology. These cells were smaller, had a reduced cytoplasmic-to-nuclear ratio and had a highly disorganized cytoskeletal architecture as indicated by aTubulin immunofluorescence (Fig. 6B) .
To further investigate how the apparent increase in the ratio of labile p-b-catenin to total b-catenin in cells expressing Fgfr3 K650E might be related to the reduced levels observed in these cells, we first examined the accumulation of p-b-catenin following the treatment of cells with the proteasome inhibitor epoximycin. While Fgfr3 K650E cells showed markedly reduced b-catenin compared with control cells, both showed an increase in b-catenin levels 5 h after addition on epoximycin (Fig. 6C) . Consistent with more robust production of p-b-catenin in Fgfr3 K650E -expressing cells, p-b-catenin accumulated to much higher levels relative to total b-catenin in Fgfr3
K650E cells compared with control cells (Fig. 6C  and D) . To examine whether the increased pool of labile p-b-catenin in Fgfr3 K650E -expressing cells was associated with increased b-catenin degradation, protein half-lives were determined by blocking protein synthesis with cycloheximide (CHX). Total b-catenin levels were again strongly reduced in FGFR3 K650E -expressing cells, but the degradation rate was not significantly accelerated ( Fig. 6E and not shown) . However, the disappearance of p-b-catenin was 7 times more rapid in Fgfr3 K650E -expressing cells (Fig. 6F) . These results suggest that Fgfr3 K650E reduces b-catenin levels, at least in part, by promoting both more rapid production and destruction of labile p-b-catenin. 
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K650E inhibits b-catenin-dependent transcription in mesenchymal cells
It was previously shown that mutant activated FGFR3, as well as FGF2 stimulation, can induce Sox9 transcription in chondrocytes and in C3H10T1/2 cells (25) . However, while we found that Sox9 RNA levels were weakly increased by Fgfr3 K650E in C3H10T1/2 cells, FGF2 stimulation had little or no effect on Sox9 RNA levels in either control or Fgfr3 K650E cells (Fig. 7A) . In contrast, Fgfr3 K650E cells exhibited increased Sox9 protein in the absence of ligand and Sox9 was further increased in these cells following FGF2 stimulation (Fig. 7A) . b-Catenin was lower in Fgfr3 K650E cells and remained low following FGF2 stimulation. Sprouty2 was induced by FGF signaling in control cells as expected (1), but its induction was much stronger in Fgfr3 K650E cells (Fig. 9A) , a result consistent with Fgfr3 K650E maintaining strong responsiveness to ligand binding (5) .
To assess the effect of . S4 ). Inhibition of TOPFlash activity corresponded to decreased b-catenin-dependent and increased Sox9 abundance (Fig. 7B) . Addition of FGF2 repressed b-catenin activity alone and augmented Fgfr3 K650E -driven repression (Fig. 7B) . The more potent repression of b-catenin activity was associated with increased Sox9 and lower b-catenin (Fig. 7B) . The use K650E -driven repression of b-catenin activity in C3H10T1/2 cells, reporter assays were performed using a sequential transfection protocol in which cells were first transfected with b-catenin, Fgfr3 K650E and TOPFlash reporter constructs and subsequently transfected with Sox9-specific or non-specific siRNA. This sequential transfection strategy was required because distinct transfection protocols were needed to introduce expression plasmid and siRNA into C3H10T1/2 cells. While Fgfr3 K650E -mediated repression of b-catenin activity was less robust using this strategy, Sox9 knockdown was achieved and decreased the repression of b-catenin-driven TOPFlash activity, particularly in cells cotransfected with Fgfr3 K650E (Fig. 7C ). These data suggest that Sox9 is at least partly responsible for Fgfr3 K650E -mediated b-catenin inhibition.
Fgfr3
K650E stabilizes Sox9 protein and cooperates with Sox9 to inhibit b-catenin-dependent transcription
The increased Sox9 protein in the absence of increased Sox9 RNA caused by Fgfr3 K650E and/or FGF2 stimulation (Fig. 7A) raised the possibility that the mutant receptor might regulate Sox9 at the post-transcriptional level. To further examine this question, C3H10T1/2 cells were transfected with Sox9 expression plasmid alone or together with increasing amounts of Fgfr3 K650E expression plasmid. Addition of Fgfr3 K650E led to a marked induction of Sox9 in a dose-dependent manner (Fig. 8A) . The increased Sox9 was associated with decreased b-catenin abundance (Fig. 8A) . To determine whether increased Sox9 protein stability was responsible for the increased Sox9, a series of experiments using CHX proteosomal inhibition to measure the half-life of Sox9 in cells with and without ectopic Fgfr3 K650E were performed. These experiments showed that Fgfr3 K650E expression increased Sox9 half-life by 3-fold ( Fig. 8B and C) .
To more directly examine the effects of Fgfr3 K650E on Sox9 and b-catenin cross-regulation, cells were transfected with Sox9 alone, Sox9 together with b-catenin or Sox9 together with b-catenin and Fgfr3 K650E . Consistent with previous results (17, 18) , b-catenin suppressed Sox9 levels, and this could be overcome by expressing more Sox9 (Fig. 8D) . However, coexpression of FGFR3 K650E with Sox9 was more effective at increasing Sox9 in the presence of b-catenin than simply transfecting more Sox9 expression plasmid (Fig. 8D) . Sox9 reduced b-catenin as expected and addition of FGFR3 K650E further reduced b-catenin (Fig. 8D) . Treatment of cells cotransfected with Fgfr3 K650E and Sox9 with the proteosomal inhibitor MG132 led to a more robust increase in b-catenin than in cells expressing Fgfr3 K650E alone (Fig. 8E) . Together, these results suggest that Fgfr3 K650E and Sox9 can cooperate to reduce b-catenin abundance in mesenchymal cells.
To determine whether Fgfr3 K650E and Sox9 can also cooperate in inhibiting b-catenin activity, TOPFlash experiments were performed following the transfection of different combinations of Fgfr3 K650E and Sox9 with b-catenin in C3H10T1/2 cells. Similar to results shown in Figure 7B , Fgfr3 K650E alone strongly suppressed b-catenin activity (Fig. 8F) . As predicted, Sox9 transfection also strongly suppressed b-catenin activity, with repression even more robust than by Fgfr3 K650E . Cotransfection of increasing amounts of Fgfr3 K650E with constant amounts of Sox9 caused a dose-dependent increase in Sox9 abundance and decrease in b-catenin activity (Fig. 8F) .
While reduced b-catenin abundance caused by Fgfr3 K650E and Sox9 may contribute to the suppression of b-catenin activity, Sox9 can also inhibit b-catenin activity independent of its ability to promote b-catenin degradation (18) . We therefore * P , 0.0002 and * * P , 0.05. Western blots of the indicated proteins were carried out from cells generated in parallel with those used in reporter assays. (C) TOPFlash reporter assays performed in C3H10T1/2 cells following sequential transfections of the indicated expression plasmids and Sox9-specific siRNA or non-specific siRNA ( * P , 0.05). Western blots of transfected cells for the indicated proteins are shown below. P-values were calculated using two-tailed t-tests.
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tested the effect of Fgfr3 K650E and combined Fgfr3 K650E plus Sox9 on the transcriptional activity of a b-catenin mutant (b-catenin T41A ) which cannot be phosphorylated by Gsk3b at T41 and as a result is not efficiently degraded by the b-catenin destruction complex (16) . Fgfr3 K650E suppressed the activity of b-catenin T41A , but similar to their relative effects on wild-type b-catenin activity, Sox9 was more effective than Fgfr3 K650E at inhibiting b-catenin T41A activity (Fig. 8F) . Cotransfection of increasing amounts of
Fgfr3
K650E with constant Sox9 caused a dose-dependent increase in Sox9 abundance that closely corresponded to a further reduction in b-catenin T41A activity (Fig. 8F) . The strong inhibition of b-catenin T41A activity occurred despite b-catenin T41A abundance being unaffected or even increased (Fig. 8F) . Taken together, these data indicate that the ability of Fgfr3 K650E to inhibit b-catenin transcriptional activity is closely correlated with its ability to increase Sox9 abundance and suggest that both mechanisms that reduce b-catenin Human
abundance and that independently inhibit b-catenin activity, contribute to b-catenin inhibition.
DISCUSSION
During skeletogenesis, FGFR3 is preferentially expressed in chondrocytes and mutations that cause inappropriate or increased FGFR3 activity suppress the process of endochondral ossification and lead to shortened bones of the appendicular skeleton. Although previous studies showed that defects in endochondral ossification in TDII were associated with a differentiation block (5), results in this study provide insight into the molecular mechanisms that underlie this defective differentiation. Here, we show that b-catenin levels and activity are down-regulated in vivo in growth plate chondrocytes and articular chondrocytes, as well as in mesenchymal cells expressing ectopic Fgfr3 K650E . b-Catenin down-regulation is likely important mechanistically in disrupting endochondral ossification in TDII, since the conditional deletion of b-catenin in growth plate chondrocytes causes a dwarfism phenotype that, like TDII, is characterized by reduced cell proliferation and suppressed endochondral ossification (17) . b-Catenin also plays an important role in the development of articular chondrocytes and its deletion in these cells or their progenitors causes joint malformations, including joint fusions (32, 37, 38) that appear similar to those described in our TDII model, as well as in a previous study describing transgenic mice expressing Fgfr3 G380R (33) . Thus, our findings strongly implicate disrupted regulation of b-catenin as a key underlying mechanism in chondrodysplasia and defective joint formation caused by mutant hyperactivation of Fgfr3. Moreover, since the severity of chondrodysplasias caused by the various FGFR3 mutations is linked to the degree of aberrant hyperactivation of the mutant receptors (3), we speculate that the spectrum of disease states caused by FGFR3 mutations is at least in part a function of the degree of canonical Wnt signaling attenuation.
Fgfr3 signaling and the control of Sox9 -b-catenin homeostasis
Sox9 is normally down-regulated in prehypertrophic chondrocytes and ectopic Sox9 expression in growth plate chondrocytes directed by the Col2a1 promoter reduced proliferation, delayed or inhibited differentiation into hypertrophic chondrocytes and resulted in a dwarfism phenotype (17, 39) . When Sox9 expression was directed to hypertrophic chondrocytes using Col10a1 promoter sequences, it impeded terminal differentiation and the expression of Vegfa and associated primary ossification center vascularization (17, 40) . Expression of Sox9 was shown to directly repress Col10a1 expression in resting and proliferating chondrocytes (13) , which fits with the close association of Col10a1 up-regulation in prehypertrophic and hypertrophic chondrocytes with Sox9 down-regulation in these cells. Interestingly, while ectopic Sox9 expression in hypertrophic chondrocytes was found to suppress terminal differentiation events, the deletion of Sox9 in growth plate chondrocyte was recently found to induce apoptosis, suppress Col10a1 expression and prevent proper hypertrophic differentiation (9, 14) . Moreover, in contrast to the finding that Sox9 directly repressed Col10a1 expression, Dy et al. (14) found that Sox9 was responsible for the direct activation of Col10a1, at least during the initial differentiation of prehypertrophic chondrocytes to hypertrophic chondrocytes. In our TDII model, Col10a1 expression appears to be appropriately initiated in prehypertrophic cells and remains strongly expressed up to the ossification front along with Sox9. These results indicate that Sox9 and Col10a1 expression are compatible and are generally in line with data indicating that Sox9 can promote Col10a1 expression (14) . However, despite the strong Col10a1 expression, TDII chondrocytes near to, and at, the chondro-osseous junction remain densely packed and fail to undergo the same degree of hypertrophy as in control growth plates. Thus, while Sox9 may have an important role in promoting the transition from prehypertrophic to hypertrophic chondrocytes, its persistent expression in hypertrophic cells appears to prevent terminal differentiation events required for efficient endochondral ossification.
The defects in chondrocyte hypertrophic differentiation and the resulting chondrodysplasia phenotype caused by forced Sox9 expression in growth plate chondrocytes (17, 39) show obvious similarities to the TDII phenotype described here and by Iwata et al. (5) , but also to the chondrodysplasia caused by deletion or inhibition of b-catenin in growth plate chondrocytes (17) . Further, Sox9 has been implicated as a negative regulator of joint formation, since it is downregulated in articular chondrocytes during joint formation (40, 41) and its expression throughout the knee joint space along with the down-regulation of b-catenin was associated with joint fusions in our TDII model. The antagonist properties of Sox9 and b-catenin in regulating chondrocyte behavior are associated with their ability to interact in cells and their reciprocal activities in promoting each others proteosomal degradation (17, 18) . The dynamics of Sox9 -b-catenin interaction and cross-regulation clearly impact the establishment, expansion and differentiation of growth chondrocytes and may similarly influence articular chondrocytes. Sox9 -b-catenin cross-regulation also predicts that events or factors that independently impact the production or accumulation of either Sox9 or b-catenin will strongly influence their potent reciprocal activities in regulating chondrocyte behavior. We show that Fgfr3 K650E can increase Sox9 stability and that increased protein stability is the likely mechanism responsible for the Figure 9 . Model for disruption of endochondral ossification and joint formation in TDII. FGFR3 K650E down-regulates b-catenin levels and activity and promotes Sox9 accumulation in mesenchymal cells. b-Catenin and Sox9 negatively regulate each other's levels and activity, so by initiating a shift in the balance toward Sox9, FGFR3 K650E may drive a feed-forward system that keeps b-catenin repressed and thereby prevents efficient chondrocyte hypertrophy and endochondral ossification. A similar system is proposed to control articular chondrocyte differentiation and joint formation. Whether the mutant receptor would initiate such a feed-forward system by downregulating b-catenin, inducing Sox9 (dashed lines), or both, remains unknown. (17, 18) . Nonetheless, by concomitantly promoting Sox9 accumulation and down-regulating b-catenin, mutant FGFR3 markedly shifts the balance between Sox9 and b-catenin in cells to favor Sox9. Since Sox9 can promote the proteosomal degradation of b-catenin, the mutant receptor is predicted to trigger a feed-forward circuit that reinforces Sox9 up-regulation by reducing b-catenin-driven Sox9 degradation (Fig. 9) . This model provides a potential explanation for increased Sox9 and decreased b-catenin protein and activity in transfected cells and may also help explain the apparent failure to down-regulate Sox9 in growth plate and articular chondrocytes of developing TDII bones. This type of feed-forward circuit may also apply to the regulation of Runx2, which has functions similar to b-catenin in promoting hypertrophic differentiation (42) , and can also be targeted for proteosomal degradation by Sox9 (43) . Thus, while it will be important to determine whether the interplay between mutant Fgfr3 and Sox9 controls Runx2 levels and activity, given the potent and reciprocal activities of Sox9 and b-catenin in governing hypertrophic chondrocyte and articular chondrocyte differentiation, this working model provides a general framework for mechanisms underlying the TDII chondrodysplasia phenotype.
Akiyama et al. (17) showed that in addition to suppressing chondrocyte differentiation, both forced Sox9 expression and b-catenin deletion reduced cell proliferation in growth plate chondrocytes. Consistent with the changes in Sox9 and b-catenin expression and activity we observed, proliferation was reduced in the growth plate of Prx1-Cre;TDII mice at E16.5. Moreover, levels of the b-catenin target c-Myc were reduced in the proliferative compartment of the growth plate of Prx1-Cre;TDII mice, and loss of c-Myc in growth plate chondrocytes is known to reduce their proliferation (32) . However, similar to Iwata et al. (5), we found modestly increased proliferation in the TDII growth plate at E14.5. These results raise the possibility that the initial exposure of chondrocytes to FGFR3 K650E might promote proliferation, but that more chronic Fgfr3 K650E exposure, perhaps through the induction of negative feedback signaling (44) or DNA damage signaling (45), leads to reduced or arrested proliferation. Interestingly, the strong suppressive effect Fgfr3 K650E had on b-catenin transcriptional activity was not rescued by inhibitors of MAPK signaling (PD98059, MEK inhibitor) or PI3K signaling (LY294002), but instead MAPK inhibition (but not PI3K inhibition) augmented repression (S.O. and P.J.H., unpublished data). Although additional studies are needed, these results suggest that negative Fgfr signaling rather than positive signaling may be responsible for downregulating b-catenin levels and activity and contribute to the TDII chondrodysplasia phenotype.
In addition to their important roles in governing chondrocyte behavior in the growth plate, cross-regulation between Sox9 and b-catenin controls chondrocyte and osteoblast fate determination in early limb bud mesenchyme (19 -21) . Previous studies showed that the overexpression of wild-type or Fgfr G380R in C3H10T1/2 cells can promote chondrogenesis (46) . Although in principal these results suggest that mutant Fgfr3 activity might impinge on fate determination between chondrocyte and osteoblast lineages, we did not observe any change in the osteoblast marker Runx2 during limb bud stages, or in osteoblast markers later during endochondral ossification in TDII model mice (Fig. 3M and N) (5) . This may be because Fgfr3 (and mutant Fgfr3 in TDII) is expressed in cells at limb bud stages that appear already committed to the chondrogenic lineage based on Sox9 expression, but is not expressed in Runx2-positive cells (Fig. 2E and F) . Moreover, besides the distal ectoderm of the E12.5 limb bud, TOPGal activity at E12.5 was restricted to central/proximal regions of condensing mesenchyme that appear to overlap with Sox9 and FGFR3 expression, and Fgfr3 K650E reduced this activity. Thus, while our in vivo data support the notion that mutant Fgfr3 can promote and/or reinforce the chondrogenic lineage by increasing Sox9 and inhibiting b-catenin activity in chondrocytes, its ability to impact osteoblast fate determination in vivo may be minimal due to its chondrocyte-restricted expression. However, we cannot completely rule out that changes in osteoblast numbers or behavior, in addition to defects in hypertrophic chondrocyte differentiation and vascularization, might contribute to the poor endochondral ossification in TDII.
Mechanism of b-catenin inhibition by Fgfr3
K650E and Sox9
b-Catenin stability is regulated by a multiprotein complex that includes of b-catenin, Axin, APC and Gsk-3b (47) . According to canonical regulation of b-catenin degradation, Gsk-3b phosphorylates primed b-catenin within this complex, which marks b-catenin for ubiquitylation and subsequent proteasome degradation in the cytoplasm (16). Topol et al. (18) showed that Sox9 promotes nuclear translocation of b-catenin together with components of the b-catenin destruction complex, which leads to enhanced phosphorylation and degradation of b-catenin in the nucleus. While Fgfr3 K650E promoted both up-regulation of Sox9 and b-catenin phosphorylation at Gsk-3b sites, we did not observe increased trafficking of endogenous b-catenin, Sox9 or Gsk-3b to the nucleus (S.O. and P.J.H., unpublished data). Thus, our results appear to be more in line with FGFR3 K650E and Sox9-driven b-catenin destruction occurring in the cytoplasm. One possibility is that the dramatic effect Fgfr3 K650E had on C3H10T1/2 cell morphology and the distribution of b-catenin within the cytoplasm might alter normal programs regulating b-catenin turnover and promote b-catenin degradation through a novel mechanism. Nonetheless, it will be important to test, using mutant Sox9 and b-catenin proteins that lack their respective interaction regions, whether Sox9-b-catenin interactions contribute to their altered turnover in Fgfr3 K650E -expressing CH310T1/2 cells and chondrocytes. Further, since our experiments using b-catenin T41A clearly indicate that mechanisms besides the control of b-catenin degradation contribute to Fgfr3 K650E -driven repression of b-catenin activity, it will be important to determine whether mechanisms such as Sox9-dependent interference with b-catenin binding to Tcf/Lef transcription factors or b-catenin cofactors (18) are involved.
Human Molecular
Finally, while results in this study provide a framework for molecular mechanisms underlying TDII and potentially other chondrodysplasia syndromes caused by activating mutations in FGFR3, they may also be relevant to various skeletal diseases caused by mutations in other FGFRs. Indeed, we found that Fgfr1, 2 and 4 with mutations equivalent to FGFR3 K650E were similarly effective at suppressing b-catenin transcriptional activity (C.-Y.S. and P.J.H., unpublished data). Therefore, the inhibition of b-CATENIN and canonical WNT signaling by mutant FGFRs may be a previously unappreciated general mechanism underlying human skeletal malformations, and perhaps defective morphogenesis in other tissues and organs systems, caused by FGFR mutations.
MATERIALS AND METHODS
Mice
Intercrosses between TDII (5) and Prx1-Cre (26) mice on a mixed background of C57BL/6 and 129 yielded Prx1-Cre;TDII mice. Mice and embryos were genotyped as described previously (5, 26) . TOPGal mice were obtained from JAX (Bar Harbor, ME, USA).
Skeletal preparation and staining
For Alcian blue/Alizarin red staining of whole skeletons, embryos were de-skinned and stained with 0.05% Alcian Blue and 0.015% Alizarin Red in 70% ethanol and 13% glacial acetic acid for 3 days, cleared in 0.5% KOH overnight and stored in glycerin. For Alcian blue and von Kossa staining of skeletal sections, tissues were fixed in 4% paraformaldehyde/PBS, decalcified in EDTA and embedded in paraffin. Sections were stained with Alcian Blue and Alizarin Red as above and counter stained with 0.05% hematoxylin and eosin. For histology of the chondro-osseous junction (Fig. 3L ), limbs were fixed with 1.5% glutaraldehyde/1.5 paraformaldehyde in DMEM overnight at 4 degrees followed by three changes of DMEM over 15 min. Tibias were dissected out, osmicated for 90 min in 1% OsO4 in DMEM, rinsed in DMEM, dehydrated from 30 to 100% EtOH, rinsed in propylene oxide and infiltrated in Spurr's epoxy (microwave assisted). Samples were cut and stained using toluidine blue 0 with basic fuchsin epoxy tissue stain from EMS (Hatfield, PA, USA).
In situ hybridization
In situ hybridization of embryos and sectioned tissue was performed using digoxigenin-UTP-labeled riboprobes (48) .
BrdU incorporation and TUNEL assays
BrdU labeling was performed for 1.5 h sectioned tissues stained using the BD Biosciences BrdU In situ Detection Kit. Anti-BrdU stained E16.5 sections were counterstained with hematoxylin. TUNEL assays was performed on fixed sections using the Roche In Situ Cell Death Detection Kit.
Immunohistochemistry, immunofluorescence and western blots
For immunohistochemistry, embryos were fixed overnight in 4% paraformaldehyde, imbedded in OCT compound and sectioned. Sections were blocked with 20% donkey or goat serum in PBS followed by overnight incubation with primary antibodies at 48C. For immunoflourescence, cells were fixed on coverslips and antibody staining performed as described previously (49) . For standard western blots, cells were lysed with RIPA buffer (50 mM Tris -HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 1.0% NP-40, 0.5% sodium deoxycholate) containing COMPLETE Protease Inhibitor cocktail (Roche). Following protein quantification using the Bradford assay, equal amounts of protein were run on 4 -12% Novex Bis -Tris gels in MOPS buffer and transferred onto PVDF membranes (Millipore). Antibodies against the following proteins were used: Sox9 Cell culture, cell transfection and reporter assays C3H10T1/2 cells were routinely cultured in DMEM containing 10% fetal bovine serum. Expression vectors used in transfections included pCDNA6V5-HIS Fgfr3 K650E pFBneoFgfr3 K650E , pcDNA3-b-catenin, pcDNA3-b-catenin T41A (a gift from Y. Lee, CST) and 5 ′ UTFlag-pcDNA3.1Sox9 [a gift from Brendan Lee (Baylor)]. C3H10T1/2 cells cultured in DMEM containing 10% fetal calf serum were transfected using FUGENE 6 reagent (Roche). For Sox9 siRNA knockdown studies, cells were first transfected with expression plasmids, TOPFlash reporter and PCMVbGal using FUGENE6 and as in the other experiments. Twenty-four hours after the plasmid transfection cells were transfected with 20 pmol Sox-9 siRNA (SCB, sc-36534) using Invitrogen's Lipofectamine 2000 reagent and protocol. Cells were harvested 24 h post siRNA transfection for reporter assays. Luciferase assays were performed in triplicate as previously described (49) using TOPFlash luciferase reporter plasmid (50) and the plasmid pCMVbGal to control for transfection efficiency. Relative luciferase activity was reported in arbitrary units after normalization for transfection efficiency.
RNA preparation and RT -PCR
Total RNA was isolated using TRIzol (Invitrogen) according to the manufacturer's protocol. RNA concentration was determined using a NanoDrop 2000c instrument (Thermo
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Human Molecular Genetics, 2012, Vol. 21, No. 21 Scientific). cDNA was generated from 1 mg of RNA sample using the SuperScript III first-strand cDNA synthesis kit (Invitrogen), and semi-quantitative RT -PCR was carried out using 1 ml of cDNA per sample and 0.2-0.3 mm concentrations of each primer. Gene targets were amplified using an empirically determined cycle number allowing for gel-based visualization of samples within the exponential amplification phase of each reaction. Equivalent volumes of each PCR were separated through 1.2% Tris borate-EDTA-agarose gels containing ethidium bromide and photographed under UV illumination.
Protein degradation and proteasomal inhibition assays
Protein half-life experiments using CHX (Sigma) and protein accumulation assays using epoximycin or MG132 (Sigma) were performed as described previously (51) . Protein accumulation and half-lives were determined from at least three independent experiments. Specific protein quantitation was performed by densitometry using ImageQuant software (GE Healthcare) and data points were plotted on a non-linear scale with time zero being set at 100%. The protein half-life was calculated using a one-phase decay equation (GraphPad Prism).
